Metastatic Cancer Drugs Global Market Report 2024

The metastatic cancer drugs market size has grown steadily in recent years. It will grow from $55.28 billion in 2023 to $57.68 billion in 2024 at a compound annual growth rate (CAGR) of 4.3%. The growth observed in the historic period can be attributed to several key factors, including the development of chemotherapy, advancements in targeted therapies, discoveries in immunotherapy, successful outcomes in clinical trials, and improvements in the diagnosis and staging of cancer. These elements collectively contributed to the progress and evolution of cancer treatment during the historical period.

The metastatic cancer drugs market size is expected to see steady growth in the next few years. It will grow to $69.46 billion in 2028 at a compound annual growth rate (CAGR) of 4.8%. The anticipated growth in the forecast period can be attributed to the evolution of precision medicine, the development of biomarker-driven therapies, advancements in liquid biopsy techniques, the adoption of patient-centric approaches, and the implementation of comprehensive genomic profiling. Major trends expected in the forecast period encompass the emergence of combination therapies, advancements in nanomedicine, a focus on long-term survivorship support, early intervention strategies, and an increased emphasis on health equity and access. These trends reflect the ongoing efforts to enhance the effectiveness and inclusivity of cancer care and treatment.

The anticipated growth in the metastatic cancer drugs market is expected to be driven by two significant factors. Firstly, the increasing prevalence of metastatic cancers is poised to contribute to market expansion. Metastatic cancer, characterized by the advanced spread of cancer to other parts of the body, is on the rise. The growing number of metastatic cancer cases has spurred the development of novel cancer medications targeting various types of metastatic cancer. Notably, the Journal of the National Cancer Institute projected in 2022 that the number of individuals living with metastatic breast, prostate, lung, colorectal, or bladder cancer, or metastatic melanoma in the United States, is expected to reach 0.69 million cases by 2025. Moreover, breast cancer surpassed lung cancer in April 2022 as the most diagnosed cancer worldwide, with an estimated 2.3 million women affected in 2021 alone, according to the Breast Cancer Research Foundation. The increasing prevalence of metastatic cancers, as evidenced by rising statistics, is a key driver for the metastatic cancer drugs market.

The evolution of precision medicine and personalized therapies is anticipated to further propel market growth. Precision medicine involves tailoring medical care and treatment to individual patients, taking into account factors such as genetic makeup, molecular profile, environment, and lifestyle. The utilization of metastatic cancer drugs in precision medicine allows for tailored treatment strategies based on the unique genetic and molecular characteristics of patients. This approach enables healthcare providers to identify targeted therapies that are more likely to be effective against specific cancer subtypes, thereby enhancing treatment outcomes and minimizing adverse effects. For example, estimates from the Personalized Medicine Coalition in October 2022 indicated that over 75,000 genetic testing kits and 300 personalized treatments will be available for individuals with various cancers and other health conditions. The evolution of precision medicine and personalized therapies, by focusing on individual patient characteristics, is a significant driver for the metastatic cancer drugs market.

Product innovation is a prominent trend in the metastatic cancer drugs market, with major players focusing on the development of novel drugs to enhance their market positions. One noteworthy example is the conditional approval granted in the European Union in January 2021 for the drug ENHERTU (trastuzumab deruxtecan) as a monotherapy for the treatment of HER2-positive metastatic breast cancer. This approval, a collaborative effort between Daiichi Sankyo Company Limited and AstraZeneca PLC, marked a significant milestone in transforming outcomes for patients with HER2-positive metastatic breast cancer in the USA and Japan. The approval in the EU further expands the reach of this novel medicine to patients in the region, addressing the increasing cases of cancers.

Major companies in the metastatic cancer drugs market are actively involved in developing novel drugs such as ZN-A-1041, an oral breast cancer medicine. ZN-A-1041, an orally administered selective tyrosine kinase inhibitor, specifically targets the human epidermal growth factor receptor 2 (HER2) and is designed to penetrate the blood-brain barrier. This drug has demonstrated potential in treating or preventing the onset of brain metastases in HER2-positive metastatic breast cancer patients. For instance, in May 2022, F. Hoffmann-La Roche AG launched ZN-A-1041, which can cross the blood-brain barrier to treat breast tumors that have spread to the brain.

In March 2023, Pfizer Inc., a US-based pharmaceutical company, confirmed its acquisition plans with Seagen Inc. for $43 billion. This strategic move is part of Pfizer's broader strategy to expand its oncology portfolio and solidify its position as a global leader in the oncology division. The acquisition of Seagen Inc., a biotechnology company specializing in antibody-based cancer medicines, complements Pfizer's existing portfolio across solid tumors and hematologic malignancies.

Major companies operating in the metastatic cancer drugs market report are Pfizer Inc., Johnson and Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, AstraZeneca PLC, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Astellas Pharma Inc., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Incyte Corporation, Ipsen SA, Seagen Inc., Exelixis Inc., Zymeworks Inc., Karyopharm Therapeutics Inc., CRISPR Therapeutics AG, Fate Therapeutics Inc., CytomX Therapeutics Inc., Spectrum Pharmaceuticals Inc., Intellia Therapeutics Inc., GlaxoSmithKline PLC, Adaptimmune Therapeutics plc.

North America was the largest region in the metastatic cancer drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the metastatic cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the metastatic cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Key categories of metastatic cancer drugs include HER2 inhibitors, immune checkpoint inhibitors, PARP inhibitors, kinase inhibitors, and others. HER2 inhibitors specifically target human epidermal growth factor receptor (HER2) to obstruct the reception of growth signals in HER2-positive cancers. These inhibitors find applications in diverse cancer types, including breast cancer, lung cancer, liver cancer, hematological cancer, brain cancer, prostate cancer, pancreatic cancer, and others. Treatment modalities involve chemotherapy, immunotherapy, hormonal therapy, surgery, and various routes of administration such as intravenous, intramuscular, and oral administration. These therapies are utilized across different healthcare settings, including hospitals, specialty clinics, and others.

The metastatic cancer drugs market research report is one of a series of new reports that provides metastatic cancer drugs market statistics, including metastatic cancer drugs industry global market size, regional shares, competitors with a metastatic cancer drugs market share, detailed metastatic cancer drugs market segments, metastatic cancer drugs market trends and opportunities, and any further data you may need to thrive in the metastatic cancer drugs industry. This metastatic cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The metastatic cancer drugs market consists of sales of drugs such as capecitabine, docetaxel, eribulin, pegylated, gemcitabine, and vinorelbine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.